Medtronic plc
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Medtronic (MDT) announced a final exchange ratio of 4.5939 shares of MiniMed (MMED) for each Medtronic share in its split-off offer. Up to 225.4 million MiniMed shares will be exchanged, with proration if oversubscribed. The offer expires October 9, 2026, unless extended.
Medtronic (MDT) received permanent CPT codes for its Altaviva and Symplicity Spyral devices. Shares are down 7.52% in 1 month and 9.33% YTD, but up 26.12% over 3 years. Analysts estimate MDT is 24.5% undervalued with a fair value of $115.38 vs. last close at $87.09. Management hinted at higher growth aspirations, to be detailed in December.
Medtronic presented 24-month data for its AltavivaTM device at the 47th AUGS Annual Scientific Meeting, showing sustained reductions in nightly nocturia episodes. The company also announced a partnership to raise awareness of pelvic floor disorders. Medtronic is a global leader in healthcare technology, with a diverse portfolio of medical devices.
Over the past 7 days, AlphAI's AI scored 21 news stories mentioning MDT (Medtronic plc). Coverage has skewed bullish: 11 bullish, 10 neutral, and 0 bearish.
Recent MDT coverage spans financial news, technology and mergers & acquisitions.
In the last 30 days, MDT insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($139K). The most active reporter was KIIL HARRY SKIP, EVP & President Cardiovascular, with 1 filing.
The set ratio defines how many MiniMed shares Medtronic shareholders will receive, influencing valuation of both entities.
Positive regulatory approval likely supports near‑term price upside.
Positive clinical data may boost investor confidence in Medtronic's urology portfolio.
Analyst initiation and a price target above current levels may lift the stock.
The hire signals continued investment in the high‑growth cardiac ablation franchise, likely supporting modest upside for the stock.
AlphAI scores every news story that mentions MDT with an AI model for sentiment and relevance, and aggregates insider trades from Medtronic plc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Medtronic (MDT) announced a final exchange ratio of 4.5939 shares of MiniMed (MMED) for each Medtronic share in its split-off offer. Up to 225.4 million MiniMed shares will be exchanged, with proration if oversubscribed. The offer expires October 9, 2026, unless extended.
2 min readMedtronic (MDT) received permanent CPT codes for its Altaviva and Symplicity Spyral devices. Shares are down 7.52% in 1 month and 9.33% YTD, but up 26.12% over 3 years. Analysts estimate MDT is 24.5% undervalued with a fair value of $115.38 vs. last close at $87.09. Management hinted at higher growth aspirations, to be detailed in December.
2 min readMedtronic presented 24-month data for its AltavivaTM device at the 47th AUGS Annual Scientific Meeting, showing sustained reductions in nightly nocturia episodes. The company also announced a partnership to raise awareness of pelvic floor disorders. Medtronic is a global leader in healthcare technology, with a diverse portfolio of medical devices.
2 min readBarclays initiated Medtronic (MDT) with an Equal Weight rating and $95 price target, citing attractive multiples and expected 2027 fundamentals. The firm's top picks include Edwards Lifesciences, Stryker, Beta Bionics, DexCom, and LivaNova. Archer Aviation (ACHR) and SpaceX (SPCX) have Strong Buy consensus, with ACHR showing more upside potential. Cathie Wood's ARK Invest bought 2.57M ACHR shares and sold 54,873 SPCX shares. ACHR is down 38% YTD but has a $11.60 avg.
1 min readMedtronic (MDT) appointed Felicia Kurz, former Siemens Healthineers SVP, as VP and GM of its Cardiac Ablation Solutions business. Kurz brings 10 years of experience in healthcare leadership. Medtronic's cardiac ablation solutions, including the Affera Sphere-9 catheter, have seen strong demand and double-digit revenue growth, according to the company.
2 min readMedtronic (MDT) offers shareholders a $4B swap to exchange shares for its diabetes unit, MiniMed. The swap, covering 80.1% of MiniMed's stock, is losing appeal, risking delays. A stall could affect share count, gross margins, and valuation. MiniMed grew 15% in Q1 2027, while MDT raised its revenue outlook to 7.25-7.75%. Management aims to close the swap by fiscal year-end.
3 min readThe VIVA Foundation presented late-breaking clinical trial results at The VEINS 2026 conference. Key findings include 88.1% ulcer healing rate with Cyanoacrylate Closure (CAC) for C6 disease, 100% technical success for the VEnice device in treating venous incompetence, and favorable 30-day results for the Abre Venous Stent System. The RAPID-PE study showed promising interim results for on-the-table mechanically channeled thrombolysis in acute intermediate-risk pulmonary embolism.
2 min readMedtronic reported an 88.1% ulcer-healing rate over two years for its VenaSeal device, with 96% U.S. insurance coverage. The study involved 125 patients, showing a median healing time of 92 days and 77.1% recurrence-free rate. Medtronic shares closed at $86.38 on Friday, with market reaction pending.
2 min readTarget (TGT), Kimberly-Clark (KMB), Consolidated Edison (ED), and Medtronic (MDT) all raised dividends despite varying stock performances. Target's dividend rose 1.8% to $1.16, KMB's to $1.28, ED's by 4.4% to $0.8875, and MDT's to $0.72. Each company's payout is covered by earnings or cash flow, with varying growth prospects and risks.
2 min readRBC Capital's Kendall Au maintained a Buy rating on Medtronic (MDT) with a $118 price target. Medtronic closed at $86.44. Analyst consensus is Moderate Buy with a $103.41 target. Q2 revenue was $9.76B, up from $8.58B last year, with net profit at $1.47B, up from $1.04B.
1 min read
